KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Moderna (MRNA) EBITDA Margin (2017 - 2026)

Moderna (MRNA) has disclosed EBITDA Margin for 10 consecutive years, with 356.81% as the latest value for Q1 2026.

  • For Q1 2026, EBITDA Margin rose 61541.0% year-over-year to 356.81%; the TTM value through Mar 2026 reached 153.35%, down 3352.0%, while the annual FY2025 figure was 158.13%, 3622.0% down from the prior year.
  • EBITDA Margin hit 356.81% in Q1 2026 for Moderna, down from 126.4% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 69.68% in Q1 2022 and bottomed at 972.22% in Q1 2025.
  • Average EBITDA Margin over 5 years is 251.18%, with a median of 109.89% recorded in 2023.
  • Year-over-year, EBITDA Margin crashed -73843bps in 2024 and then soared 61541bps in 2026.
  • Moderna's EBITDA Margin stood at 31.08% in 2022, then plummeted by -99bps to 0.21% in 2023, then crashed by -60530bps to 128.99% in 2024, then rose by 2bps to 126.4% in 2025, then tumbled by -182bps to 356.81% in 2026.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 356.81%, 126.4%, and 25.59% for Q1 2026, Q4 2025, and Q3 2025 respectively.